ClinicalTrials.gg
Status unknownNCT05186922Updated Mar 9, 2022

The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis

A Phase 1/2 interventional study of CM326 and Placebo in Moderate-to-severe Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2022-03-09.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Feb 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd — 4 open to participants now, 5 under way, 3 of them phase 3. Dermatitis, Atopic · Keymed Biosciences Co.Ltd.

Planned enrollment
15th of 18
54 · median 170
Started
2022
with 3 others
Phase 1/2
3 of 18
none open now
Registered
4th of 18
by date

Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 15th largest by planned enrollment, is one of 4 that started in 2022, is one of 3 in phase 1/2, and was the 4th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

4 of the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled multiple dose escalation study to evaluate the safety, tolerance, PK, PD, immunogenicity and preliminary efficacy of CM326 in moderate-severe AD subjects.

Read the detailed description

The study consists of 3 periods, a up-to-4-week Screening Period, a 12-week randomized Treatment Period and a 12-week Safety Follow-up Period.

03

Conditions studied

  • Moderate-to-severe Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • With confirmed Atopic Dermatitis (AD) at least 12 months before the screening
  • Eczema Area and Severity Index (EASI) score ≥16 at screening and baseline
  • Investigator's Global Assessment (IGA) score ≥3 at screening and baseline
  • Body Surface Area (BSA) of involvement of atopic dermatitis ≥10% at screening and baseline
  • The weekly mean score of daily peaks in pruritus NRS at baseline ≥4
  • Provide signed

Exclusion criteria

Exclusion Criteria:

  • Not enough washing-out period for previous therapy.
  • Presence of other concomitant and poorly controlled serious diseases or recurrent chronic diseases, including but not limited to active infections, cardiovascular and cerebrovascular diseases, pulmonary tuberculosis or other pathogen infections, diabetes mellitus, diseases, (HIV) infection, active , or parasitosis, neoplasm malignant, etc.
  • Patients with severe hepatic or renal impairment, characterized by (AST) or alanine aminotransferase (ALT) level > 2 times of (ULN), total >1.5 times of upper limit of normal (ULN) or serum creatinine level > upper limit of normal (ULN).
  • Womens who are pregnant or breastfeeding, or who plan to become pregnant during the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (estimated)

Study arms

  • Experimental
    CM326 55 mg, once every two weeks (Q2W)

    55mg for 6 doses, every 2 weeks, subcutaneous (SC)

    Biological: CM326

  • Experimental
    CM326 110 mg, once every two weeks (Q2W)

    110mg for 6 doses, every 2 weeks, subcutaneous (SC)

    Biological: CM326

  • Experimental
    CM326 110 mg, once every four weeks (Q4W)

    110mg for 3 doses, every 4 weeks, subcutaneous (SC)

    Biological: CM326

  • Experimental
    CM326 220 mg, once every two weeks (Q2W)

    220mg for 6 doses, every 2 weeks, subcutaneous (SC)

    Biological: CM326

  • Experimental
    CM326 220 mg, once every four weeks (Q4W)

    220mg for 3 doses, every 4 weeks, subcutaneous (SC)

    Biological: CM326

  • Placebo comparator
    Placebo

    Placebo for 6 doses, every 2 weeks, subcutaneous (SC) and placebo for 3 doses, every 4 weeks, subcutaneous (SC)

    Other: Placebo

Interventions

  • BiologicalCM326

    CM326 injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of Adverse Events (AE)

    Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: Up to week 24

Secondary outcomes

  1. Pharmacokinetics (PK) parameter: Time to reach peak concentration (Tmax)

    Time to reach peak concentration (Tmax)

    Time frame: Up to Week 24

  2. Pharmacokinetics (PK) parameter : Peak Plasma concentration (Cmax)

    Peak Plasma concentration (Cmax)

    Time frame: Up to Week 24

  3. Pharmacokinetics (PK) parameter : Area under the plasma concentration-time curve (AUC)

    Area under the plasma concentration-time curve (AUC)

    Time frame: Up to Week 24

  4. Pharmacokinetics (PK) parameter : Clearance rate (CL/F)

    Clearance rate (CL/F)

    Time frame: Up to Week 24

  5. Pharmacokinetics (PK) parameter : Elimination half life (T1/2z)

    Elimination half life (T1/2z)

    Time frame: Up to Week 24

  6. Pharmacodynamics (PD): Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration

    Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration

    Time frame: Up to Week 24

  7. Pharmacodynamics (PD): Changes from baseline in eosinophil count after CM326 administration

    Changes from baseline in eosinophil count after CM326 administration

    Time frame: Up to Week 24

  8. Pharmacodynamics (PD): Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration

    Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration

    Time frame: Up to Week 24

  9. Pharmacodynamics (PD): Changes from baseline in plasma interleukin-5 (IL-5) concentration after CM326 administration

    Changes from baseline in plasma interleukin-5 (IL-5) concentration after CM326 administration

    Time frame: Up to Week 24

  10. Pharmacodynamics (PD): Changes from baseline in plasma interleukin-13 (IL-13) concentration after CM326 administration

    Changes from baseline in plasma interleukin-13 (IL-13) concentration after CM326 administration

    Time frame: Up to Week 24

  11. Pharmacodynamics (PD): Changes from baseline in serum periostin concentration after CM326 administration

    Changes from baseline in serum periostin concentration after CM326 administration

    Time frame: Up to Week 24

  12. Immunogenicity: anti-drug antibody (ADA) and neutralizing antibody (Nab)

    Detection of anti-drug antibody (ADA) and neutralizing antibody (Nab)

    Time frame: Up to Week 24

  13. Proportion of patients with Investigator's Global Assessment (IGA) score = 0-1 at each visit

    IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)

    Time frame: Up to Week 24

  14. Proportion of patients with IGA reduction from baseline of ≥2 points at each visit

    IGA is a 6-point scale ranging from 0 (clear) to 5 (very severe)

    Time frame: Up to Week 24

  15. Proportion of patients with Eczema Area and Severity Index (EASI)-50 (≥50 percent reduction in EASI scores from baseline) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to Week 24

  16. Proportion of patients with Eczema Area and Severity Index (EASI)-75 (≥75 percent reduction in EASI scores from baseline) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to Week 24

  17. Proportion of patients with Eczema Area and Severity Index (EASI)-90 (≥90 percent reduction in EASI scores from baseline) at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to Week 24

  18. Change from baseline in Eczema Area and Severity Index (EASI) score at each visit

    The EASI score was used to measure the severity and extent of atopic dermatitis (AD) and measures erythema, infiltration, excoriation and lichenification on 4 anatomic regions of the body: head, trunk, upper and lower extremities. The total EASI score ranges from 0 to 72 points, with the higher scores reflecting the worse severity of AD

    Time frame: Up to Week 24

  19. Proportion of patients with reduction of Pruritus Numerical Rating Scale (NRS) of ≥3 and ≥4 points from baseline

    The range of NRS is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: Up to Week 24

  20. Percent change from baseline in Numerical Rating Scale (NRS)

    The range of NRS is from 0 (no itch)-10 (worst imaginable itch)

    Time frame: Up to Week 24

  21. Body surface area (BSA) of involvement of atopic dermatitis

    Change from baseline in percent of BSA

    Time frame: Up to Week 24

  22. Changes from baseline in Dermatology Life Quality Index (DLQI) at each visit

    The DLQI is a 10-item, validated questionnaire used in clinical practice and clinical trials to assess the impact of AD disease symptoms and treatment on quality of life

    Time frame: Up to Week 24

07

Study locations

1 of 1 sites recruiting
  • Peking University People's hospital
    Beijing, Beijing, China
    Recruiting
    • Jianzhong Zhang · Contact
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2022 (actual). Primary completion is estimated for Jan 2023, 11 months after the start.

Of 25 industry-sponsored phase 1/2 interventional studies under Dermatitis, Atopic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 38. This study's planned 11 months is below that.

Counting every sponsor, half of 29 studies reached it within 22 months; a quarter within 8 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 13, 2021
First posted
Jan 11, 2022
StartActual
Feb 17, 2022
Primary completionEst.
Jan 2023
CompletionEst.
Jan 2023
Last update
Mar 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05186922
Responsible party
Sponsor
First posted
Jan 11, 2022
Start date
Feb 17, 2022
Primary completion
Jan 2023 (estimated)
Completion
Jan 2023 (estimated)
Last update
Mar 9, 2022

Study contacts

Qian Jia
Contact
qianjia@keymedbio.com
+862888610620

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion